On August 15, 2012 The New England Journal of Medicine published favorable results from the Enzalutamide NCT0097431 Study. The clinical trial was funded by Medivation Inc. (sponsor) and Astellas Pharma (collaborator) Global Development. The United States National Institute of Health provides the clinical trial over sight.
Study design (late stage cancer) can be beneficial for facilitating approval with the (FDA) Food and Drug Administration process for securing a marketable avenue. People in the study had received a series of chemo with docetaxel, and despite castration the undesirable cells continued to multiply (progressive). Castration reduces the flow of testosterone.
The tumor (undesired cells) acts to increase the number of receptors to facilitate the connections needed to continue growing. So, despite the chemo and castration acting to reduce the available androgen, having more receptors helps the tumor use a larger amount of the smaller quantity now avaliable. When tumor growth continues after chemo and castration the medical system will note a failed trial of traditional hormone therapy and chemo. This is where Enzalutamide appears to help disassemble the process for tumor production.
Enzalutamide disrupts necessary connections in the androgen (hormone) development pathway. Prostate cancer growth (progressive) is dependent upon the connections in the androgen pathway for functional expansion. Disrupting this needed path for expansion translates to prolonged human survival.
The clinical trial found Enzalutamide significantly prolonged the survival of men with metastic castration resistant prostate cancer. The drug Enzalutamide appears to help men with prostate cancer live longer.
The side effects of the drug report 5 of 800 men experienced seizure like activity. Hot flashes, fatigue and diarrhea were also noted. Home Care Path encourages family's to follow the progression of the drug Enzalutamide through the Food and Drug Administration's approval process.
Home Care Path www.homecarepath.com is a leading senior care provider serving south central Wisconsin. Services include:
-in home staffing with help for ADL's and IADL's
-inpatient advocacy for safe successful hospital stays
-crisis intervention with transitional counseling
-temporary help with a scheduled day surgery
-down sizing home contents when stuff matters
-communicate face to face on the computer across long distances
Simply call 608-432-4286 to schedule an in home interview. 2012 rates are 20.00 per hour. Email lkutzke@homecarepath.onmicrosoft.com We accept long term care insurance. We can be there when you are working. Services are tax deductible. Valuing home and human life.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment